

Curriculum Vitae

Personal information **Helene Van De Ven**

Work experience

1. Employer: University of Antwerp
 - Start date: 102005
 - End date: 082012
 - Position: Doctoral researcher /post_doctoral researcher
 - Activities: Scientific research activities in domain of pharmaceutical technology/pharmaceutical development. Organisation of practical lessons in the field of pharmaceutical technology.
 - Country: Belgium
2. Employer: Federal Agency for medicines and health products
 - Start date: 102012
 - End date: 122014
 - Position: Scientific file manager
 - Activities: Validation and file management of marketing authorisation applications through national, decentralised and mutual_recognition procedure. Secretary of the National Commission for Medicines for human use (January 2013_March 2015)
 - Country: Belgium
3. Employer: Federal Agency for medicines and health products
 - Start date: 012015
 - End date:
 - Position: Quality assessor
 - Activities: Assessment of quality module of medicinal products in framework of marketing authorisation applications and variations (CP, NAT & DCP/MRP), clinical trial applications (CTA) and scientific advice (NAT & EU).
 - Country: Belgium

Education and training

1. Subject: University of Antwerp
 - Start date: 091999
 - End date: 062005
 - Qualification: Master in Pharmaceutical Sciences
 - Organisation:
 - Country: Belgium
2. Subject: University of Antwerp
 - Start date: 102005
 - End date: 042012
 - Qualification: PhD in Pharmaceutical Sciences
 - Organisation: Pharmaceutical Technology/Pharmaceutical development/Design of experiments (DoE)
 - Country: Belgium

Additional information

Publications

1) H. Van de Ven, C. Paulussen, P._B. Feijens, A. Matheeussen, P. Rombaut, P. Kayaert, G. Van den Mooter, W. Weyenberg, P. Cos, L. Maes, A. Ludwig PLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to Fungizone® and AmBisome®. J. Control. Release 2012; DOI: 10.1016/j.jconrel.2012.05.037. 2) H. Van de Ven, J. Vandervoort, W. Weyenberg, S. Apers, A. Ludwig Mixture designs in the optimisation of PLGA nanoparticles: influence of organic phase composition on β _aescin encapsulation. J. Microencapsul. 2012; 29 (2): 115_125. 3) H. Van de Ven, M. Vermeersch, R.E. Vandenbroucke, A. Matheeussen, S. Apers, W. Weyenberg, S.C. De Smedt, P. Cos, L. Maes, A. Ludwig Intracellular drug delivery in Leishmania infected macrophages: evaluation of saponin loaded PLGA nanoparticles. J. Drug Target. 2012; 20 (2): 142_154. 4) H. Van de Ven, M. Vermeersch, A. Matheeussen, J. Vandervoort, W. Weyenberg, S. Apers, P. Cos, L. Maes, A. Ludwig PLGA nanoparticles loaded with the antileishmanial saponin β _aescin: factor influence study and in vitro efficacy evaluation. Int. J. Pharm. 2011; 420 (1): 122_132. 5) J. Van Herck, G. De Meyer, W. Martinet, R. Salgado, B. Shivalkar, R. De Mondt, H. Van de Ven, A. Ludwig, P. Van Der Veken, L. Van Vaeck, H. Bult, A. Herman, C. Vrints Multi_slice computed tomography with N1177 identifies ruptured atherosclerotic plaques in rabbits. Basic Res. Cardiol. 2010; 105 (1): 51_59. 6) H. Van de Ven, M. Vermeersch, T. Shunmugaperumal, J. Vandervoort, L. Maes, A. Ludwig Solid lipid nanoparticle (SLN) formulations as a potential tool for the reduction of cytotoxicity of saponins. Pharmazie 2009; 64 (3): 172_176.

Projects

Budget analyst Direktorat_General PRE (period December 2015 _ October 2021)

Memberships

Other Relevant Information